321 related articles for article (PubMed ID: 18401811)
1. Athletes' knowledge and views on OTC medication.
Mottram D; Chester N; Atkinson G; Goode D
Int J Sports Med; 2008 Oct; 29(10):851-5. PubMed ID: 18401811
[TBL] [Abstract][Full Text] [Related]
2. Self-reported attitudes of elite athletes towards doping: differences between type of sport.
Alaranta A; Alaranta H; Holmila J; Palmu P; Pietilä K; Helenius I
Int J Sports Med; 2006 Oct; 27(10):842-6. PubMed ID: 16586338
[TBL] [Abstract][Full Text] [Related]
3. Australian athletes' knowledge of the WADA Prohibited Substances List and performance enhancing substances.
Orr R; Grassmayr M; Macniven R; Grunseit A; Halaki M; Bauman A
Int J Drug Policy; 2018 Jun; 56():40-45. PubMed ID: 29550541
[TBL] [Abstract][Full Text] [Related]
4. Problems of the use of pseudoephedrine by athletes.
Pokrywka A; Tszyrsznic W; Kwiatkowska DJ
Int J Sports Med; 2009 Aug; 30(8):569-72. PubMed ID: 19382058
[TBL] [Abstract][Full Text] [Related]
5. Over-the-counter drug use amongst athletes and non-athletes.
Chester N; Reilly T; Mottram DR
J Sports Med Phys Fitness; 2003 Mar; 43(1):111-8. PubMed ID: 12629472
[TBL] [Abstract][Full Text] [Related]
6. [Medication, athletes and doping regulations].
Hartgens F
Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
[TBL] [Abstract][Full Text] [Related]
7. Caffeine consumption amongst British athletes following changes to the 2004 WADA prohibited list.
Chester N; Wojek N
Int J Sports Med; 2008 Jun; 29(6):524-8. PubMed ID: 18027309
[TBL] [Abstract][Full Text] [Related]
8. Between medical treatment and performance enhancement: an investigation of how elite athletes experience Therapeutic Use Exemptions.
Overbye M; Wagner U
Int J Drug Policy; 2013 Nov; 24(6):579-88. PubMed ID: 23582632
[TBL] [Abstract][Full Text] [Related]
9. Clean Olympians? Doping and anti-doping: the views of talented young British athletes.
Bloodworth A; McNamee M
Int J Drug Policy; 2010 Jul; 21(4):276-82. PubMed ID: 20056401
[TBL] [Abstract][Full Text] [Related]
10. Health and doping in elite-level cycling.
Lentillon-Kaestner V; Hagger MS; Hardcastle S
Scand J Med Sci Sports; 2012 Oct; 22(5):596-606. PubMed ID: 21392123
[TBL] [Abstract][Full Text] [Related]
11. Hormone abuse in sports: the antidoping perspective.
Barroso O; Mazzoni I; Rabin O
Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
[TBL] [Abstract][Full Text] [Related]
12. Detection of GH abuse in sport: Past, present and future.
Barroso O; Schamasch P; Rabin O
Growth Horm IGF Res; 2009 Aug; 19(4):369-74. PubMed ID: 19482501
[TBL] [Abstract][Full Text] [Related]
13. Rheumatological prescribing in athletes: a review of the new World Anti-Doping Agency guidelines.
Smith R; Barnsley L; Kannangara S; Mace A
Rheumatology (Oxford); 2004 Dec; 43(12):1473-5. PubMed ID: 15292526
[TBL] [Abstract][Full Text] [Related]
14. Doping in sport: a review of elite athletes' attitudes, beliefs, and knowledge.
Morente-Sánchez J; Zabala M
Sports Med; 2013 Jun; 43(6):395-411. PubMed ID: 23532595
[TBL] [Abstract][Full Text] [Related]
15. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
Nikolopoulos DD; Spiliopoulou C; Theocharis SE
Fundam Clin Pharmacol; 2011 Oct; 25(5):535-63. PubMed ID: 21039821
[TBL] [Abstract][Full Text] [Related]
16. Doping control, providing whereabouts and the importance of privacy for elite athletes.
Valkenburg D; de Hon O; van Hilvoorde I
Int J Drug Policy; 2014 Mar; 25(2):212-8. PubMed ID: 24462318
[TBL] [Abstract][Full Text] [Related]
17. [Doctors belonging to the Senegalese Association of Sport Medicine and doping in sports: survey on knowledge and attitudes].
Dièye AM; Diallo B; Fall A; Ndiaye M; Cissè F; Faye B
Sante; 2005; 15(3):167-70. PubMed ID: 16207578
[TBL] [Abstract][Full Text] [Related]
18. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
Striegel H; Rössner D; Simon P; Niess AM
Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
[TBL] [Abstract][Full Text] [Related]
19. Korean national athletes' knowledge, practices, and attitudes of doping: a cross-sectional study.
Kim T; Kim YH
Subst Abuse Treat Prev Policy; 2017 Feb; 12(1):7. PubMed ID: 28196542
[TBL] [Abstract][Full Text] [Related]
20. An (un)desirable trade of harms? How elite athletes might react to medically supervised 'doping' and their considerations of side-effects in this situation.
Overbye M
Int J Drug Policy; 2018 May; 55():14-30. PubMed ID: 29477956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
